target="_blank" rel="nofollow" href="#ulink_47857ff2-caf3-5086-b2f3-f3be30d35b54">15Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al: FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181–200.
16Hoeben BA, Bussink J, Troost EG, Oyen WJ, Kaanders JH: Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. Acta Oncol 2013;52:1257–1271.
17Span PN, Bussink J: Biology of hypoxia. Semin Nucl Med 2015;45:101–109.
18Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J: Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012;9:674–687.
19Padhani AR, Krohn KA, Lewis JS, Alber M: Imaging oxygenation of human tumours. Eur Radiol 2007;17:861–872.
20Wouters BG, Koritzinsky M: Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008;8:851–864.
21Meijer TW, Kaanders JH, Span PN, Bussink J: Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 2012;18:5585–5594.
22Leszczynska KB, Foskolou IP, Abraham AG, Anbalagan S, Tellier C, Haider S, et al: Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. J Clin Invest 2015;125:2385–2398.
23Wijsman R, Kaanders JH, Oyen WJ, Bussink J: Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography. Q J Nucl Med Mol Imaging 2013;57:244–256.
24Yaromina A, Krause M, Baumann M: Individualization of cancer treatment from radiotherapy perspective. Mol Oncol 2012;6:211–221.
25Begg AC, Stewart FA, Vens C: Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011;11:239–253.
26Hoff CM, Lassen P, Eriksen JG, Hansen HS, Specht L, Overgaard M, et al: Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? – Results from the randomized DAHANCA 5 and 7 trials. Acta Oncol 2011;50:1006–1014.
27Lambin P, Ramaekers BL, van Mastrigt GA, et al: Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst Rev 2009;3:CD006158.
28Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, et al: Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 2012;30:1777–1783.
29Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, et al: Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer. Clin Cancer Res 2014;20:1345–1354.
30Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135–146.
31Bussink J, van Herpen CM, Kaanders JH, Oyen WJ: PET-CT for response assessment and treatment adaptation in head and neck cancer. Lancet Oncol 2010;11:661–669.
32Lopci E, Grassi I, Chiti A, Nanni C, Cicoria G, Toschi L, et al: PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am J Nucl Med Mol Imaging 2014;4:365–384.
33Krohn KA, Link JM, Mason RP: Molecular imaging of hypoxia. J Nucl Med 2008;49(suppl 2):129S–148S.
34Troost EG, Laverman P, Philippens ME, Lok J, van der Kogel AJ, Oyen WJ, et al: Correlation of [18F]FMISO autoradiography and pimonidazole (corrected) immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 2008;35:1803–1811.
35Troost EG, Bussink J, Kaanders JH, van Eerd J, Peters JP, Rijken PF, et al: Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother Oncol 2005;76:194–199.
36Shi K, Bayer C, Astner ST, Gaertner FC, Vaupel P, Schwaiger M, et al: Quantitative analysis of [18F]FMISO PET for tumor hypoxia: correlation of modeling results with immunohistochemistry. Mol Imaging Biol 2017;19:120–129.
37van Elmpt W, Zegers CM, Reymen B, Even AJ, Dingemans AM, Oellers M, et al: Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion. Eur J Nucl Med Mol Imaging 2016;43:240–248.
38Taylor E, Yeung I, Keller H, Wouters BG, Milosevic M, Hedley DW, et al: Quantifying hypoxia in human cancers using static PET imaging. Phys Med Biol 2016;61:7957–7974.
39Carlin S, Zhang H, Reese M, Ramos NN, Chen Q, Ricketts SA: A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers. J Nucl Med 2014;55:515–521.
40O’Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al: Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005;61:1493–1502.
41Ljungkvist AS, Bussink J, Kaanders JH, Rijken PF, Begg AC, Raleigh JA, et al: Hypoxic cell turnover in different solid tumor lines. Int J Radiat Oncol Biol Phys 2005;62:1157–1168.
42Ljungkvist AS, Bussink J, Kaanders JH, van der Kogel AJ: Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. Radiat Res 2007;167:127–145.
43Ljungkvist AS, Bussink J, Rijken PF, Raleigh JA, Denekamp J, van der Kogel AJ: Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol